Analysts forecast that Chimerix Inc (NASDAQ:CMRX) will report $940,000.00 in sales for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Chimerix’s earnings, with estimates ranging from $500,000.00 to $1.45 million. Chimerix reported sales of $680,000.00 in the same quarter last year, which indicates a positive year-over-year growth rate of 38.2%. The company is scheduled to announce its next earnings report on Monday, August 6th.
On average, analysts expect that Chimerix will report full year sales of $3.59 million for the current fiscal year, with estimates ranging from $2.29 million to $5.07 million. For the next fiscal year, analysts anticipate that the firm will report sales of $10.75 million per share, with estimates ranging from $3.20 million to $25.00 million. Zacks’ sales averages are an average based on a survey of analysts that that provide coverage for Chimerix.
Chimerix (NASDAQ:CMRX) last issued its quarterly earnings results on Monday, May 7th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.43) by $0.01. Chimerix had a negative return on equity of 31.97% and a negative net margin of 1,736.95%. The firm had revenue of $0.79 million during the quarter, compared to the consensus estimate of $1.12 million.
Chimerix traded down $0.04, reaching $4.65, during trading hours on Friday, Marketbeat Ratings reports. 340,988 shares of the company’s stock were exchanged, compared to its average volume of 190,822. Chimerix has a twelve month low of $4.17 and a twelve month high of $5.94. The company has a market cap of $229.22 million, a P/E ratio of -3.08 and a beta of 1.26.
In other news, Director Ernest Mario sold 52,553 shares of the firm’s stock in a transaction dated Monday, May 14th. The stock was sold at an average price of $4.64, for a total value of $243,845.92. Following the completion of the sale, the director now directly owns 12,905 shares in the company, valued at approximately $59,879.20. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Over the last 90 days, insiders sold 130,368 shares of company stock valued at $616,495. 12.50% of the stock is currently owned by company insiders.
Several institutional investors and hedge funds have recently modified their holdings of the company. Wells Fargo & Company MN grew its stake in shares of Chimerix by 46.1% in the 1st quarter. Wells Fargo & Company MN now owns 33,569 shares of the biopharmaceutical company’s stock valued at $175,000 after buying an additional 10,598 shares during the period. Schwab Charles Investment Management Inc. grew its stake in shares of Chimerix by 5.4% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 211,655 shares of the biopharmaceutical company’s stock valued at $980,000 after buying an additional 10,764 shares during the period. Alps Advisors Inc. grew its stake in shares of Chimerix by 21.0% in the 1st quarter. Alps Advisors Inc. now owns 63,099 shares of the biopharmaceutical company’s stock valued at $328,000 after buying an additional 10,967 shares during the period. Quantitative Systematic Strategies LLC acquired a new stake in shares of Chimerix in the 1st quarter valued at about $115,000. Finally, MetLife Investment Advisors LLC acquired a new stake in shares of Chimerix in the 1st quarter valued at about $127,000. Institutional investors own 72.65% of the company’s stock.
Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.